3 Bonding Products Brand, Copper Winding Wire Producer and Prescription Brands Company Stocks With a Strong Future Roadmap: Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals
- November 19, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals: ROE of 18.5% to 25.5% and FY22 to FY26 revenue CAGR of 10.5% to 22.7%. Prices as of 18 Nov 2026.
Quick Answer
The three adhesive, enamelled wire and gastro drug stocks to watch are Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals. Their return on equity ranges from 18.5% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 22.7%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Ram Ratna Wires has the fastest revenue growth at 22.7% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Adhesive, enamelled wire and gastro drug stocks offer a focused view of a sector where demand keeps widening. Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals cover an adhesives and sealants maker, a winding wires maker and a branded pharmaceuticals company.
This list covers three adhesive, enamelled wire and gastro drug stocks with complete current figures: Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Adhesive, Enamelled Wire and Gastro Drug Stocks?
Adhesive, enamelled wire and gastro drug stocks are listed companies that make adhesives, sealants and construction chemicals, make copper and aluminium winding wires for motors and transformers, and make branded medicines for heart, stomach and brain care. Their earnings depend on construction activity, electrical orders and medicine demand.
Adhesive, Enamelled Wire and Gastro Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Pidilite Industries | 1,530.2 | 150,953 | 56.4 | 35.1 | 22.6 | 0.04 |
| Ram Ratna Wires | 511.3 | 5,049 | 39.5 | 11.3 | 18.5 | 1.13 |
| Torrent Pharmaceuticals | 4,610.7 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing adhesive, enamelled wire and gastro drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in adhesive, enamelled wire and gastro drug stocks can use the coming numbers to test whether growth is holding.
Why Do Adhesive, Enamelled Wire and Gastro Drug Stocks Have a Strong Roadmap in India?
Adhesive, enamelled wire and gastro drug stocks have a strong roadmap in India because strong building and repair activity, steady demand from motor and transformer makers and steady demand for branded medicines keep widening the market for these companies.
- Adhesives. Carpenters and builders use trusted brands.
- Winding wires. Motors and transformers need copper wire.
- Branded medicines. Doctors prescribe trusted brands.
Why Pidilite Industries Features Among These Adhesive, Enamelled Wire and Gastro Drug Stocks
Among the adhesive, enamelled wire and gastro drug stocks on this list, Pidilite Industries is India’s leading adhesives and construction chemicals company and the maker of Fevicol, Dr. Fixit, M-Seal and Fevikwik, among other brands.
Revenue rose from Rs 9,957 crore in FY22 to Rs 14,867 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 1,207 crore in FY22 to Rs 2,471 crore in FY26, which works out to a compound annual growth rate of 19.6%.
In the June 2026 quarter, revenue grew 21.0% year on year to Rs 4,644 crore, while net profit rose 30.3% to Rs 884 crore. The company has a return on equity of 22.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 150,953 crore. The stock trades at a P/E of 56.4, above the industry P/E of 35.1.
Roadmap: The company has a strong brand and a vast distribution network, and it continues to add products in waterproofing, paints and construction chemicals. Premium categories and new launches contribute to growth in housing and renovation.
What to watch: Check volume growth in consumer and bazaar products and the trend in raw material prices.
Why Ram Ratna Wires Features Among These Adhesive, Enamelled Wire and Gastro Drug Stocks
Among the adhesives brand, winding wire and branded medicine shares on this list, Ram Ratna Wires makes winding wires, conductors and related products used in transformers, motors, generators and electrical equipment. It supplies major manufacturers of power and industrial machines.
Revenue rose from Rs 2,295 crore in FY22 to Rs 5,195 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 54.2 crore in FY22 to Rs 109 crore in FY26, which works out to a compound annual growth rate of 19.0%.
The company has a return on equity of 18.5%, a debt to equity ratio of 1.13 and a market capitalisation of Rs 5,049 crore. The stock trades at a P/E of 39.5, above the industry P/E of 11.3.
Roadmap: The company is benefiting from higher spending on power transmission, renewable energy and electrical equipment. Added capacity and a wider product range help it serve large equipment makers.
What to watch: Track winding wire volumes, copper pass-through pricing and new capacity.
Why Torrent Pharmaceuticals Features Among These Adhesive, Enamelled Wire and Gastro Drug Stocks
Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Pidilite Industries vs Ram Ratna Wires vs Torrent Pharmaceuticals on Key Financials
The table below sets the three adhesive, enamelled wire and gastro drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Pidilite Industries | 9,957 | 14,867 | 10.5% | 2,471 | 16.6% |
| Ram Ratna Wires | 2,295 | 5,195 | 22.7% | 109 | 2.1% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Pidilite Industries has the largest FY26 revenue at Rs 14,867 crore, and Ram Ratna Wires shows the fastest revenue growth with a 22.7% compound annual rate. A useful habit with adhesive, enamelled wire and gastro drug stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Adhesive, Enamelled Wire and Gastro Drug Stocks
Every theme carries risks that deserve a check before any decision. For these adhesive, enamelled wire and gastro drug stocks, the main points are: Long-term adhesives brand, winding wire and branded medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
- Component costs. Copper, chips and other inputs can move margins.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter adhesive, enamelled wire and gastro drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Adhesive, Enamelled Wire and Gastro Drug Stocks
Adhesive, enamelled wire and gastro drug stocks reward patient research into demand, execution and financial strength. Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals each have a clear plan to grow. Based on the 18 November 2026 close, Pidilite Industries trades at Rs 1,530.2, Ram Ratna Wires at Rs 511.3 and Torrent Pharmaceuticals at Rs 4,610.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these adhesive, enamelled wire and gastro drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track adhesive, enamelled wire and gastro drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are adhesive, enamelled wire and gastro drug stocks?
Ans. Adhesive, enamelled wire and gastro drug stocks are listed companies that make adhesives, sealants and construction chemicals, make copper and aluminium winding wires for motors and transformers, and make branded medicines for heart, stomach and brain care. Their earnings depend on construction activity, electrical orders and medicine demand. This list looks at three of them, Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which adhesive, enamelled wire and gastro drug stocks are covered in this list?
Ans. This list covers Pidilite Industries, Ram Ratna Wires and Torrent Pharmaceuticals. Based on the 18 November 2026 close, Pidilite Industries traded at Rs 1,530.2, Ram Ratna Wires at Rs 511.3 and Torrent Pharmaceuticals at Rs 4,610.7. Their return on equity ranges from 18.5% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 22.7%.
Why do adhesive, enamelled wire and gastro drug stocks have a strong future roadmap in India?
Ans. Adhesive, enamelled wire and gastro drug stocks have a strong roadmap in India because strong building and repair activity, steady demand from motor and transformer makers and steady demand for branded medicines keep widening the market for these companies. The main drivers are as follows. Adhesives. Carpenters and builders use trusted brands. Winding wires. Motors and transformers need copper wire. Branded medicines. Doctors prescribe trusted brands. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Pidilite Industries performed financially?
Ans. Revenue rose from Rs 9,957 crore in FY22 to Rs 14,867 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 1,207 crore in FY22 to Rs 2,471 crore in FY26, which works out to a compound annual growth rate of 19.6%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 4,644 crore, while net profit rose 30.3% to Rs 884 crore. The company has a return on equity of 22.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 150,953 crore. The stock trades at a P/E of 56.4, above the industry P/E of 35.1. Looking ahead, the company has a strong brand and a vast distribution network, and it continues to add products in waterproofing, paints and construction chemicals. Premium categories and new launches contribute to growth in housing and renovation.
How has Ram Ratna Wires performed financially?
Ans. Revenue rose from Rs 2,295 crore in FY22 to Rs 5,195 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 54.2 crore in FY22 to Rs 109 crore in FY26, which works out to a compound annual growth rate of 19.0%. The company has a return on equity of 18.5%, a debt to equity ratio of 1.13 and a market capitalisation of Rs 5,049 crore. The stock trades at a P/E of 39.5, above the industry P/E of 11.3. Looking ahead, the company is benefiting from higher spending on power transmission, renewable energy and electrical equipment. Added capacity and a wider product range help it serve large equipment makers.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What risks should investors check before buying adhesive, enamelled wire and gastro drug stocks?
Ans. Investors should check a few risks before buying adhesive, enamelled wire and gastro drug stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Component costs. Copper, chips and other inputs can move margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of adhesive, enamelled wire and gastro drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.